Therapy Focus

“Drug resistance is the single most important cause of cancer treatment failure and carries a massive burden to patients, healthcare providers, drug developers and society. It is estimated that Multidrug Resistance (MDR) plays a major role in up to 50% of cancer cases.”

Cancer Drug Resistance
BioPharm Reports
VennBio Ltd.
January 2009

chart_therapy2Rescue Therapeutics has seen signals of efficacy in in vitro and/ in vivo studies for several types of cancers and in synergy with many chemotherapy agents.  Our most advanced work, however is for second-line ovarian cancer patients and patients with Non-Hodgkin’s lymphoma.  Our in vivo studies in both areas have shown dramatic efficacy when RTI-79 is given in conjunction with doxorubicin or DOXIL®.  Most recently we have also seen significant results in in vitro models of triple negative breast cancer.

For more about our most advanced results, click here: